Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 297

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 297
---
 Company entered into the
October 2024 bridge loan agreements (the “Bridge Loans”), pursuant to which the Company obtained a bridge loan from the lenders
thereto including certain related parties (the “Bridge Loan Lenders”). The Bridge Loans shall bear interest at 8% per annum
until maturity and the Company agreed to pay the lenders an additional risk premium equal to 30% of their respective loan amount. In October
2024, the Company amended the Bridge Loans pursuant to which the Bridge Loans may be extended beyond March 31, 2025 and until June 30,
2025, subject to the Registration Statement effectiveness not later than March 31, 2025 and the fulfillment of additional cumulative conditions.
Furthermore, upon the occurrence of a Qualifying IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary
Shares equal to two times their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the
lowest price per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial
public offering. The chairman of our board of directors is a lender under one of the Bridge Loans. As of November 20, 2024, the Company
received $117.5 out of the $500 proceeds.

<div align='center'>F-45

Ordinary Shares

Regentis Biomaterials Ltd.

PRELIMINARY PROSPECTUS

ThinkEquity

. 2025</div>

Through and including , 2025 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

<div align='center'>PART II

INFORMATION NOT REQUIRED IN PROSPECTUS</div>

Item 6. Indemnification of Directors, Officers and Employees.

Under the Companies Law, a
company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office
holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of the
duty of care but only if a provision authorizing such exculp